Low-certainty evidence suggests that off-label fluoxetine may decrease weight compared with placebo .
However , low-certainty evidence suggests an increase in the risk for dizziness , drowsiness , fatigue , insomnia and nausea following fluoxetine treatment
BACKGROUND Fluoxetine is a serotonin reuptake inhibitor indicated for major depression .
It is also thought to affect weight control : this seems to happen through appetite changes result ing in decreased food intake and normalisation of unusual eating behaviours .
However , the benefit-risk ratio of this off-label medication is unclear .
OBJECTIVES To assess the effects of fluoxetine for overweight or obese adults .
Weight suppression and weight rebound in ex-smokers treated with fluoxetine.
Fluoxetine 's effect ( 30 mg , 60 mg , and placebo ) on postcessation weight gain was studied among participants from a r and omized , double-blind 10-week smoking cessation trial who met strict criteria for abstinence and drug levels . It was hypothesized that ( a ) fluoxetine would dose-dependently suppress postcessation weight gain and ( b ) drug discontinuation would produce dose-dependent weight rebound . During the on-drug phase , placebo participants gained weight linearly ( M = 2.61 kg ) . exceeding both fluoxetine groups ( 30-mg group M = 1.33 kg , 60-mg group M = 1.25 kg ) . Weight suppression was initially greater for 60 mg than 30 mg , but both were followed by weight gain . Six months off drug produced greater dose-dependent weight rebound for 60 mg than 30 mg or placebo . Considering both on- and off-drug phases , weight gain for 60 mg of fluoxetine ( M = 6.5 kg ) was comparable with that for placebo ( M = 4.7 kg ) but greater than that for 30 mg ( M = 3.6 kg ) . Fluoxetine appears to forestall postcessation weight gain , allowing time for the weight-conscious smoker to focus on quitting smoking rather than on preventing weight gain
Low-certainty evidence suggests that off-label fluoxetine may decrease weight compared with placebo .
However , low-certainty evidence suggests an increase in the risk for dizziness , drowsiness , fatigue , insomnia and nausea following fluoxetine treatment
BACKGROUND Fluoxetine is a serotonin reuptake inhibitor indicated for major depression .
It is also thought to affect weight control : this seems to happen through appetite changes result ing in decreased food intake and normalisation of unusual eating behaviours .
However , the benefit-risk ratio of this off-label medication is unclear .
OBJECTIVES To assess the effects of fluoxetine for overweight or obese adults .